Ubs Group Ag Coll Plant Biotechnologies LTD Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Coll Plant Biotechnologies LTD stock. As of the latest transaction made, Ubs Group Ag holds 11,947 shares of CLGN stock, worth $43,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,947

Previous 7,142 67.28%

Holding current value

$43,964

Previous $35,000 68.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.28 - $5.45 $20,565 - $26,187	4,805 Added 67.28%	11,947 $59,000
Q2 2024 Aug 13, 2024	BUY	$4.84 - $6.75 $11,432 - $15,943	2,362 Added 49.41%	7,142 $35,000
Q1 2024 May 13, 2024	BUY	$4.72 - $6.15 $22,561 - $29,397	4,780 New	4,780 $25,000
Q3 2023 Nov 09, 2023	SELL	$5.4 - $8.05 $4,633 - $6,906	-858 Reduced 13.1%	5,690 $31,000
Q2 2023 Aug 11, 2023	SELL	$6.6 - $8.23 $9,609 - $11,982	-1,456 Reduced 18.19%	6,548 $53,000
Q1 2023 May 12, 2023	BUY	$6.74 - $12.99 $6,497 - $12,522	964 Added 13.69%	8,004 $56,000
Q4 2022 Feb 08, 2023	SELL	$4.71 - $9.5 $10,013 - $20,197	-2,126 Reduced 23.19%	7,040 $58,000
Q3 2022 Nov 10, 2022	BUY	$6.3 - $9.99 $10,407 - $16,503	1,652 Added 21.99%	9,166 $62,000
Q2 2022 Aug 10, 2022	BUY	$8.0 - $11.19 $32,680 - $45,711	4,085 Added 119.13%	7,514 $60,000
Q1 2022 May 16, 2022	SELL	$8.97 - $16.4 $16,477 - $30,126	-1,837 Reduced 34.88%	3,429 $38,000
Q4 2021 Feb 14, 2022	BUY	$12.0 - $22.48 $63,192 - $118,379	5,266 New	5,266 $86,000
Q3 2021 Nov 15, 2021	SELL	$16.0 - $21.75 $32,160 - $43,717	-2,010 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$13.55 - $22.45 $27,235 - $45,124	2,010 New	2,010 $43,000

Others Institutions Holding CLGN

# of Institutions

Shares Held

2.01M

Call Options Held

Put Options Held

View Full List

About CollPlant Biotechnologies Ltd

Ticker CLGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,086,500
Market Cap $40.8M
Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering tech...

More about CLGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account